The tumoricidal potential of the dual prodrug, PrAg-U2/FP59, has been successfully verified both in vitro on several malignant urokinase and anthrax toxin receptors expressing cell lines (nanomolar to picomolar IC50 values) [83,209,213], and in vivo, both in murine syngeneic and human xenograft tumor models of diverse origin, where significant anti-tumor effects were observed following local and systemic PrAg-U2/FP59 administration [209,214,215]. Here, ANTXR1 is linked to neoplasm.